Astellas Pharma and Kyowa Kirin have reached an agreement with the U.S. government to lower drug prices in U.S. Medicaid and provide the drugs under the most-favored-nation (MFN) framework. The agreement is believed to be the first of its kind involving Japanese companies.
Astellas Pharma and Kyowa Kirin announced that they have reached an agreement with the U.S. government to lower drug prices under the U.S. Medicaid program and provide the drugs on a most-favored-nation (MFN) basis.
The agreement is believed to mark the first entry by Japanese companies into a similar framework.